In 2024, the field of cancer therapeutics has witnessed remarkable progress in targeting Claudin 18.2 (CLDN18.2). As a protein highly expressed in several malignancies—particularly gastrointestinal cancers such as gastric and pancreatic cancer—CLDN18.2 has emerged as a highly promising therapeutic target. Antibody-drug conjugates (ADCs) developed against this target, including Zolbetuximab, IBI-343, LM-302, and SHR-A1904, have shown encouraging preclinical and clinical results. These innovations

Johnson & Johnson, the 138-year-old global healthcare giant, with its iconic baby powder becoming a household staple across generations. However, beginning in the 1990s, the company was swept into a mounting legal crisis centered on allegations that its talc-based products caused cancer—a controversy that would eventually grow into one of the largest product liability litigations in U.S. history. As of 2025, over 38,000 plaintiffs worldwide have filed lawsuits, with cumulative claims exceed

Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS Recommended for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) April 23, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the National Institute for Health and Care Excellence (NICE) has issued positive final guidance recommending Joenja® (leniolisib) for reimburse

ImCheck Announces Oral Presentation of Updated ICT01 Efficacy Data in First-line AML at the ASCO Annual Meeting 2025 April 23, 2025 – ImCheck Therapeutics announced today an oral presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2025, taking place from May 30 to June 3, in Chicago, Illinois, USA. The presentation will focus on results from its ongoing open-label, randomized Phase I/II study EVICTION, including updated efficacy, safety and dose-selection dat

– Oral presentation will serve as first presentation of detailed results from the Phase 3 VERITAC-2 clinical trial – April 23, 2025 -- Arvinas, Inc. (Nasdaq: ARVN) today announced that data from the global Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant versus fulvestrant in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer will be presented as a late-breaking oral presentation at

April 23, 2025 -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that updated data from the company’s ongoing Phase 1/1b clinical trial of ficerafusp alfa in 1L (first line) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) will be highlighted in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual

— Oral presentation Tuesday, June 3, 2025 in Chicago — April 23, 2025 -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that Phase 1/2 interim readout data from its U.S. NXC-201 NEXICART-2 trial in relapsed/refractory AL Amyloidosis has been selected for oral presentation at the upcoming 2025 American Society of Clinical Oncology Annual Mee

April 23, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a strategic collaboration with Catalent, a global leader in advanced delivery technologies, clinical development, and manufacturing solutions for therapeutics. Under the agreement, Catalent will conduct formulation development and clinical manufacturing activities for Silexion's n

In April 2021, Swiss pharmaceutical giant Roche celebrated the approval of its novel anti-influenza drug, Baloxavir Marboxil, in China. As the world’s first single-dose oral influenza treatment, Baloxavir quickly captured industry attention with its disruptive convenience and rapid symptom relief. However, Roche’s victory was short-lived. Just three months later, CSPC Ouyi Pharmaceutical, a subsidiary of Chinese pharmaceutical powerhouse CSPC Pharmaceutical Group, filed an application to launch

In July 2024, Swiss pharmaceutical giant Roche filed a lawsuit in a California district court that thrust Stanford University professors Maximilian Diehn and Ash Alizadeh into the center of a major controversy. This commercial dispute over cancer liquid biopsy technology not only involves $70 million in startup funding and a multibillion-dollar diagnostics market, but also exposes deep-rooted tensions between academic entrepreneurship and corporate interests in the biopharmaceutical sector. At t